|
1. http://emedicine.medscape.com/article/804757-overview, see also http://www.healthline.com/galecontent/inborn-errors-of-metabolism and http://en.wikipedia.org/wiki/Inborn_error_of_metabolism
2. Centers for Disease Control and Prevention (CDC). Impact of expanded newborn screening--United States, 2006. MMWR Morb Mortal Wkly Rep 2008 Sep 19;57(37):1012-5.
3. www.prostateconditions.org/events/pcaw/materials/YearEndReport2005
4. Schröder FH, Hugosson J, Roobol MJ, ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320-8, 2009.
5. http://www.cancer.gov/cancertopics/pdq/screening/breast/patient
6. Morgan D, Sylvester H, Lucas FL, Miesfeldt S Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting. Fam Cancer 2009 Apr 4.
7. Morgan D, Sylvester H, Lucas FL, Miesfeldt S. and The American Cancer Society guidelines for breast screening with magnetic resonance imaging: an argument for genetic testing. Cancer 113:3116-20, 2008.
8. Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26:4282-8, 2008.
9. Duijm LE, Louwman MW, Groenewoud JH, et al. Inter-observer variability in mammography screening and effect of type and number of readers on screening outcome. Br J Cancer 24;100:901-7, 2009.
10. Geller BM, Bowles EJ, Sohng HY, et al. Radiologists' performance and their enjoyment of interpreting screening mammograms. Am J Roentgenol 192:361-9, 2009. See also Resource use and cost of diagnostic workup of women with suspected breast cancer. Lee DW, Stang PE, Goldberg GA, et al. Breast J. 2009 Jan-Feb pg: 85-92, and Application of computed aided detection in breast masses diagnosis. Changizi V, Giti M, Kheradmand AA. Indian J Cancer 2008 45:164-6, 2008.
11. Anderson K, Jacobson JS, Heitjan DF, et al. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med 144: 397-406, 2006 See also The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Metcalfe KA, Lynch HT, Ghadirian P, et al. Gynecol Oncol 96: 222-6, 2005
12. Nosov V, Su F, Amneus M, et al. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol 2009 Mar 12.
13. http://www.ovariancancer.jhmi.edu/ca125qa.cfm#firstandsecond
14. Karl J, Wild N, Tacke M, et al.Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers. Clin Gastroenterol Hepatol 6:1122-8, 2008.
|